Alx Oncology Holdings (ALXO) Operating Expenses (2019 - 2026)

Alx Oncology Holdings' Operating Expenses history runs 8 years deep, the most recent figure standing at $19.0 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 40.4% year-over-year to $19.0 million; the TTM figure through Mar 2026 stood at $91.2 million (down 33.22% YoY), while the FY2025 annual figure was $104.0 million, down 26.99% from the prior year.
• Operating Expenses came in at $19.0 million for Q1 2026 at Alx Oncology Holdings, down from $23.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $53.3 million in Q3 2023 to a low of $19.0 million in Q1 2026.
• A 5-year average of $33.1 million and a median of $32.2 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 107.31% in 2022 and sank 40.4% in 2026, its largest moves.
• Alx Oncology Holdings' Operating Expenses stood at $32.2 million in 2022, then jumped by 49.05% to $48.0 million in 2023, then sank by 36.25% to $30.6 million in 2024, then dropped by 24.8% to $23.0 million in 2025, then declined by 17.61% to $19.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $19.0 million, $23.0 million, and $22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison